Development of novel method of non-viral efficient gene transfer into neonatal cardiac myocytes.
To establish new treatment for cardiovascular disease, the development of safe and highly efficient vectors is necessary. Especially, non-viral vectors are considered to be ideal for human gene therapy, since recent adverse events with retroviral or adenoviral vectors have highlighted the issue of safety. Although we previously reported safety and high efficiency of HVJ-liposome method, we have modified the envelope of HVJ (Sendai virus). In this novel non-viral vector, the envelope of HVJ alone was utilized as a carrier to deliver proteins, genes and oligodeoxynucleotides (ODN). Thus, we optimized the transfection efficiency of HVJ-envelope vector into neonatal cardiac myocytes in this study, since cardiac myocytes is one of the most difficult cells to be transfected. HVJ-envelope, obtained after complete destruction of HVJ genome, containing FITC-labeled ODN or luciferase plasmid was incubated with cardiac myocytes. In addition, the concentration of protamine sulfate was modified (0-700 microg/ml) to increase transfection efficacy. Without HVJ-envelope vector, few cells showed fluorescence, whereas most cells demonstrated fluorescence with HVJ-envelope vector. Consistent with the high transfection efficiency of ODN, high luciferase activity was also detected using HVJ-envelope vector. Moreover, the transfection efficiency varied according to the concentration of protamine sulfate. No obvious cytotoxicity was observed in cells transfected with HVJ-envelope vector. The present study demonstrated the development of a highly efficient novel non-viral vector for cardiac myocytes, suggesting that further development may provide a new useful tool for research and clinical gene therapy in the field of cardiovascular disease.
Tashiro
Hironori
H
Division of clinical gene therapy, graduate school of medicine, Osaka university, Japan.
Aoki
Motokuni
M
Isobe
Mitsuaki
M
Hashiya
Naotaka
N
Makino
Hirofumi
H
Kaneda
Yasufumi
Y
Ogihara
Toshio
T
Morishita
Ryuichi
R
D000818:Animals; D000831:Animals, Newborn; D002478:Cells, Cultured; D016650:Fluorescein-5-isothiocyanate; D005456:Fluorescent Dyes; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D006352:Heart Ventricles / Q000166:cytology; D007267:Injections; D008081:Liposomes / Q000378:metabolism; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D009206:Myocardium / Q000166:cytology / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000821:virology*; D009841:Oligonucleotides / Q000235:genetics; D010957:Plasmids; D011479:Protamines / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D029082:Sendai virus / Q000235:genetics* / Q000502:physiology*; D014162:Transfection / Q000379:methods*; D014759:Viral Envelope Proteins / Q000235:genetics*
D005456:Fluorescent Dyes; D008081:Liposomes; D009841:Oligonucleotides; D011479:Protamines; D014759:Viral Envelope Proteins; D008156:Luciferases; D016650:Fluorescein-5-isothiocyanate